Yu Xiaoping, Luo Yuanqiong, Zhou Yong, Zhang Qianyong, Wang Jian, Wei Na, Mi Mantian, Zhu Jundong, Wang Bin, Chang Hui, Tang Yong
Department of Public Health, School of Preclinical Medicine, Chengdu Medical College, Chengdu, Sichuan 610081, P R China.
Int J Oncol. 2008 Sep;33(3):555-63.
It is well established that statins display potent anticancer activity in several types of proliferating tumor cells. However, how to promote the sensitivity of statins to mammary cancer is yet to be completely deciphered. The purpose of this study was to investigate whether breast cancer susceptibility gene 1 (BRCA1) overexpression sensitizes mammary cancer cells to statins. MCF-7 cells, which have only one wild-type BRCA1 allele, were transfected with pcDNA3-beta-HA-hsBRCA1 plasmids via liposomes to reconstitute BRCA1 overexpression human breast cancer cell line, and tumoral xenografts with BRCA1 overexpression were subsequently established in BALB/c nude mice. Then, the inhibitory activity of lovastatin on cancer cells and tumoral xenografts, and the underlying mechanism involving in cell-cycle regulatory proteins were analyzed. The proliferative ability of MCF-7 cells treated with lovastatin was reduced compared to normal, and further decreased in the presence of excess BRCA1, detected by methyl thiazolyl tetrazolium and flow cytometry techniques in vitro or by 5-bromodeoxyuridine incorporation in vivo. Additionally, the mRNA and protein expression of cyclin D1, cyclin-dependent kinase 4 (CDK4) and retinoblastoma protein (pRb), was further down-regulated under exposure to lovastatin in condition of BRCA1 overexpression, but the expression of p21WAF1/CIP1, a cyclin-dependent kinase inhibitor (CDKI), was further up-regulated, both in vitro and in vivo detected with quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot analysis. Moreover, we found the further reduced volume of tumoral xenografts treated with lovastatin in the presence of BRCA1 overexpression. Our results suggest that BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway, which will provide an innovative experimental framework to study control of breast cancer cell proliferation.
他汀类药物在多种增殖性肿瘤细胞中显示出强大的抗癌活性,这一点已得到充分证实。然而,如何提高他汀类药物对乳腺癌的敏感性仍有待完全阐明。本研究的目的是探讨乳腺癌易感基因1(BRCA1)过表达是否能使乳腺癌细胞对他汀类药物敏感。MCF-7细胞只有一个野生型BRCA1等位基因,通过脂质体将pcDNA3-β-HA-hsBRCA1质粒转染到该细胞中,以重建BRCA1过表达的人乳腺癌细胞系,随后在BALB/c裸鼠中建立BRCA1过表达的肿瘤异种移植模型。然后,分析洛伐他汀对癌细胞和肿瘤异种移植的抑制活性,以及涉及细胞周期调节蛋白的潜在机制。通过体外的甲基噻唑基四氮唑和流式细胞术技术或体内的5-溴脱氧尿苷掺入法检测,与正常情况相比,用洛伐他汀处理的MCF-7细胞的增殖能力降低,并且在存在过量BRCA1的情况下进一步降低。此外,在BRCA1过表达的条件下,暴露于洛伐他汀时,细胞周期蛋白D1、细胞周期蛋白依赖性激酶4(CDK4)和视网膜母细胞瘤蛋白(pRb)的mRNA和蛋白表达进一步下调,但细胞周期蛋白依赖性激酶抑制剂(CDKI)p21WAF1/CIP1的表达在体外和体内均通过定量实时聚合酶链反应(qRT-PCR)和蛋白质印迹分析检测到进一步上调。此外,我们发现在BRCA1过表达的情况下,用洛伐他汀处理的肿瘤异种移植体积进一步减小。我们的结果表明,BRCA1过表达通过调节细胞周期蛋白D1-CDK4-p21WAF1/CIP1途径使癌细胞对洛伐他汀敏感,这将为研究乳腺癌细胞增殖的控制提供一个创新的实验框架。